Oncology innovation is driving new treatment options, with Iovance, Merit Medical and Kura advancing

Halozyme, Repligen, Iovance, Arcutis and Precigen have been highlighted in this Industry Outlook art

New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedica

TD Cowen analyst Nicholas Lorusso maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Buy and

SAN CARLOS, Calif., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) (

Shares of Iovance Biotherapeutics Inc. (NASDAQ:IOVA) are trending Friday morning, continuing a momen

Shares of Iovance Biotherapeutics are trending Friday morning after a momentum surge pushed the biot

Iovance Biotherapeutics Inc. (NASDAQ:IOVA) is trading at a 52-week high on Thursday, despite having

Iovance Biotherapeutics stock hits a 52-week high as investors weigh Moderna-Merck cancer data, Amta

Does Iovance Biotherapeutics (IOVA) have what it takes to be a top stock pick for momentum investors

UBS analyst David Dai maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Neutral and raises t

Dow Jones down 300 points, Deere & Co shares up 7.9% after beating earnings expectations. SCTX,

Iovance Biotherapeutics, Inc. delivered a breakout Q2 '26 for Amtagvi sales, with management guiding

Dow Jones up 200 points on Wed. Estee Lauder & other top stocks record gains after reporting str

Mizuho analyst Mara Goldstein maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Outperform a

Iovance's revenue rose 66% last quarter due to strong demand for Amtagvi. The company also cut its l

Barclays analyst Etzer Darout maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Overweight a

Citizens analyst Reni J. Benjamin maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Market O

Iovance rises 43% after Q2 results top estimates as Amtagvi sales beat forecasts, boosting revenues

The mean of analysts' price targets for Iovance Biotherapeutics (IOVA) points to a 28% upside in the

Iovance Biotherapeutics NASDAQ: IOVA reported record second-quarter revenue and gross margin, driven

Iovance Biotherapeutics is rated a buy, driven by strong Q2 results, surging Amtagvi sales, and prom

Iovance Biotherapeutics Inc (NASDAQ:IOVA) shares are surging Thursday after the cancer therapy compa

Iovance Biotherapeutics, Inc. (IOVA) Q2 2026 Earnings Call Transcript

Gainers Creative Medical Tech (NASDAQ:CELZ) stock increased by 107.8% to $1.39 during Thursday'

Iovance Biotherapeutics (IOVA) came out with a quarterly loss of $0.11 per share versus the Zacks Co

US stocks mixed on Thurs. Dow Jones down 50 pts. Motorola Solutions Inc shares up 9.5% after reporti

Gainers Creative Medical Tech (NASDAQ:CELZ) stock increased by 86.9% to $1.25 during Thursday's

Iovance Biotherapeutics (NASDAQ:IOVA) affirms FY2026 sales outlook from $350.000 million-$370.000 mi

U.S. Amtagvi Revenue Reaches ~$91M and Total Revenue Increased 66% Year-over-Year Gross Margin Incre

SAN CARLOS, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA),

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

SAN CARLOS, Calif., July 17, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) (

Iovance Biotherapeutics is showing steady operational and financial progress, supporting a speculati

The biotech is clearly innovative, but sometimes that's not enough.

https://www.sec.gov/Archives/edgar/data/1425205/000110465926075778/iova-20260618xs3asr.htm

First T cell therapy for a solid tumor cancer and first treatment option approved in Australia for a

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovati

Chardan Capital analyst Geulah Livshits maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Bu

Iovance Biotherapeutics (NASDAQ:IOVA) sees FY2026 sales of $350.000 million-$370.000 million vs $370

Iovance Biotherapeutics (NASDAQ:IOVA) reported quarterly losses of $(0.19) per share which missed th

U.S. stock futures fall 250 points, Highpeak Energy shares drop 7%. Other stocks also down in pre-ma

U.S. stock futures fall 250 points, Highpeak Energy shares drop 7%. Other stocks also down in pre-ma

Iovance stock jumps despite no news as investors watch short interest and promising early data from

Top Wall Street analysts changed outlook on top names. Check out all changes, including upgrades, do